• Verification code
  • Optimal Prices
    Buying products on this site guarantees the best price
  • Flexible Batches
    Flexible batch size to meet different needs of global customers
  • Prompt Delivery
    Warehouses in multiple cities to ensure timely delivery
  • Quality Assurance
    Strict process parameter control to ensure product quality
  • One-to-one Customization
    One-to-one custom synthesis for special structural needs

Alectinib-[3,3,4,5,5-d5]

General Information
Catalog: BLP-013430
Molecular Formula: C30H29D5N4O2
Molecular Weight: 487.65
Chemical Structure
Alectinib-[3,3,4,5,5-d5]
Description Labelled Alectinib. Alectinib, marketed as Alecensa, is an oral drug that blocks the activity of anaplastic lymphoma kinase (ALK) and is used to treat non-small-cell lung cancer (NSCLC). Alectinib has a low potential for interactions. While it is metabolised by the liver enzyme CYP3A4, and blockers of this enzyme accordingly increase its concentrations in the body, they also decrease concentrations of the active metabolite M4, resulting in only a small overall effect. Conversely, CYP3A4 inducers decrease alectinib concentrations and increase M4 concentrations. Interactions via other CYP enzymes and transporter proteins cannot be excluded but are unlikely to be of clinical significance.
Synonyms Alecensa-d5; 9-Ethyl-6,6-dimethyl-8-[4-(4-morpholinyl)-1-piperidinyl]-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile-d5
IUPAC Name 9-ethyl-6,6-dimethyl-11-oxo-8-(3,3,4,5,5-pentadeuterio-4-morpholinopiperidin-1-yl)-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile
Related CAS 1256580-46-7 (unlabelled)
Purity >95%; 98% atom D

Interested in our Service & Products?
Need detailed information?

USA
  • International:
  • US & Canada (Toll free):
  • Email:
  • Fax:
UK
  • Email:
Copyright © 2024 BOC Sciences. All Rights Reserved.
Inquiry Basket